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ABSTRACT 
An analytical method was developed for estimation of Emtricitabine and Tenofovir Disoproxil Fumarate in drug product by using high 
performance liquid chromatography. The chromatographic separation was performed on column Cosmosil C18 (250mm x 4.6ID, Particle size: 
5micron) using methanol: water (70:30 v/v) as mobile phase with flow rate of 0.8 ml/min. The detection was carried by using UV-300-M 
detector at 266 nm wavelength. The retention times of Emtricitabine and Tenofovir Disoproxil Fumarate were found to be 3.561 and 5.478 min 
respectively. Run time was observed as 5.54 min and 7.05 min respectively for Emtricitabine and Tenofovir Disoproxil Fumarate. Validation 
was performed as per ICH guidelines which include accuracy, precision, linearity, specificity, LOD, LOQ, ruggedness and robustness all of these 
were found within standard range as per ICH norms. Preparation of mobile phase is very simple & does not require lengthy procedure. 
Proposed method was found to be accurate and specific for routine quality control of pharmaceutical dosage form like bulk and tablet dosage 
form. 
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INTRODUCTION  
One of the deadliest and unmanageable chronic health 
catastrophes is HIV/AIDS. Fixed dose combinations(FDCs) 
form the main stay in clinical management of HIV-1 infection 
as they offer several advantages over single products with 
respect to storage, prescribing, dispensing, patient use, 
consumption and disease management.1 Emtricitabine (EMT) 
is the most important nucleoside reverse transcriptase 
inhibitor(NRTI)used for the treatment of HIV infection in 
adults. Emtricitabine acts as an analogue of cytidine. By using 
this drug to inhibiting the reverse transcriptase and the 
enzyme that copies human immune deficiency virus RNA 
into novel viral Deoxyribo nucleic acid.2 Emtricitabine may 
divide down measure of HIV in blood (viral weight). 
Emtricitabine may in like way escalate measure of T cells 
called CD4 cells. Hacking down measure of HIV in blood 
severs down probability of death that happen when your 
protected structure is slight (entrepreneurial defilements).  
Emtricitabine can cut down measure of HIV or viral weight, 
in patient’s body and can indirectly increase cd4 cells. both of 
these headways are connected with more important safe 
structure and decrease probability of guaranteed 
contamination.3 chemical name of Emtricitabine is 4-amino-
5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl] 
pyrimidin-2-one 
 
Figure No.1: structure of Emtricitabine 
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Molecular formula C₈H₁₀FN₃O₃S with Molecular weight-
247.24 g/mol. Emtricitabine Soluble in Acetonitrile & 
methanol and slightly soluble in water and Appearance is 
White to off white powder4. Tenofovir Disoproxil 
Fumarate(TDF) belongs to class of antiretroviral drugs 
known as nucleotide reverse transcriptase inhibitor, 
analogue of adenosine 5. Tenofovir Disoproxil Fumarate is 
fumaric acid salt of the bisisopropoxycarbonyl-oxymethyl 
ester derivative,Tenofovir. Tenofovir Disoproxil fumarate is 
a fumarate salt prepared from equimolar amount of 
Tenofovir Disoproxil and fumaric acid.6chemical Name is -
(2E)-but-2-enedioic acid; bis({[(propan-2-yloxy) carbonyl] 
oxy} methyl) {[(2R)-1-(6-amino-9H-purin-9-yl) propan-2-yl] 
oxy} methane phosphonate. 
 
Figure No.2: Tenofovir Disoproxil fumarate 
  
Molecular formula C23H34N5O14P with Molecular weight-
635.52g / mol. Tenofovir Disoproxil fumarate Soluble in 
methanol, slightly soluble in water, very slightly soluble in 
dichloromethane & sparingly soluble in acetone and 
Appearance is White to off-white crystalline powder.7 The 
method developed is precise, simple and precise RP-HPLC 
method to determine Emtricitabine and Tenofovir Disoproxil 
Fumarate in pharmaceutical dosage forms. 
MATERIAL AND METHOD 
Chemical and solvent  
Emtricitabine and Tenofovir Disoproxil Fumarate were 
Obtained as gift samples from LUPIN Pharmaceutical Ltd, 
Pune, India. Solvents will be made available commercially 
from Pharmaceutical Lab in Pune, India 
Selection of Mobile phase  
For effective separation and in order to determine optimum 
Chromatographic Conditions mixture of different solvent 
were tried initially to find the ideal mobile phase. Finally, 
mobile phase was selected as Methanol: Water (70:30 v/v). 
This mobile phase gave high resolution and minimal tailing. 
Methanol has better solubility in combination with water 
and gave lesser column backpressure compared to 
acetonitrile. 
Preparation of Mobile phase  
Mobile phase was prepared by mixing 70ml of methanol and 
30ml water. mobile phase was filtered through 0.45µ 
Membrane filter and then it was ultra-sonicated for 30 
minutes 
.Preparation of standard stock solution  
An accurately weighted 10mg of pure drug of Emtricitabine 
and Tenofovir Disoproxil Fumarate and separately 
transferred to 10 ml volumetric flask. both the drug was 
dissolved in 10 ml of solvent used as mobile phase. With 
shaking and then volume Was made up to the mark to get 
1000ppm of standard Stock solution of individual drug. It 
was ultra-sonicated and filtered through 0.20 µ membrane 
filter  
Selection of analytical wavelength  
Dilutions are prepared from standard stock solutions of 
Emtricitabine and Tenofovir Disoproxil Fumarate, were 
scanned separately used for wavelength detection as well as 
simultaneous determination of drugs before RP-HPLC 
Method, it is also for solubility studies. The isobastic point 
was found to be 266 nm 
 
Figure No.3: Overlain spectrum of Emtricitabine and 
Tenofovir Disoproxil Fumarate.
 
 
System Suitability Parameters 
Table No. 1 – Parameters of System Suitability 
Sr. No Parameters  Emtricitabine Tenofovir Disoproxil Fumarate 
1 Retention time (min) 3.561 5.478 
2 Resolution (R) 6.47 
3 No of theoretical plate (N) 8219 7514   
4 Tailing factor  1.04        1.18       
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Figure No.4 - Chromatogram of Emtricitabine with their retention time 
 
Figure No. 5 - Chromatogram of Tenofovir Disoproxil Fumarate with their retention time 
 
Assay preparation of Tablet formulation: 
20 tablets were accurately weighed and average weight was 
determined. Powdered tablet equivalent to 200 mg of 
Emtricitabine and   was transferred into a 200 ml volumetric 
flask. 10 ml of water was added and sonicated for 10 
minutes to disperse the tablet powder. Then 130 ml of 
methanol was added and sonicated for 25 minutes with 
intermittent shaking. The volume was made upto mark with 
methanol after cooling and mixed well, filtered through 0.45 
µ nylon filter. First 2 ml of the filtrate was discarded and 5 
ml of this filtrate was diluted to 50 ml with diluent and 
mixed well to get concentration of Emtricitabine as about 
200µg/ml, Tenofovir Disoproxil Fumarate 300µg/ml, The 
blank, standard and sample solutions were injected and 
result are given in table no 1  
 
Table No. 2– Assay Data of Emtricitabine and Tenofovir Disoproxil Fumarate. 
Sr no 
 
parameters 
 
Drug 
Emtricitabine Tenofovir Disoproxil Fumarate 
1 Label claim (%/tab) 200 mg                      300 mg 
2 Drug content(%) 200.14 300.8 
3 % RSD 0.14 0.20 
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Fig.No.6- Chromatogram of Emtricitabine and Tenofovir Disoproxil Fumarate. 
 
Validation.  
The method was validated for Linearity, precision, accuracy, 
Robustness, Ruggedness, limit of detection, limit of 
quantification.  
A. Linearity 
A calibration curve was obtained by plotting peak area on Y-
axis and concentration on X-axis. linearity OF Emtricitabine 
and Tenofovir Disoproxil Fumarate was found to be in the 
range of 10-50µg/ml and 15-75µg/ml. correlation coefficient 
value was found to be 0.9994 and 0.9995 for Emtricitabine 
and Tenofovir Disoproxil Fumarate. 
 
Table 3: Linearity data of Emtricitabine and Tenofovir Disoproxil Fumarate 
Concentration of 
Emtricitabine (µg/ml) 
Peak area  
 
Concentration of Tenofovir 
Disoproxil Fumarate (µg/ml) 
Peak area  
10 359283   15 283852 
20 878147   30 766242 
30 1416658   45 1296985 
40 1979742   60 1838271 
50 2567232   75 2373994 
 
 
Figure No.7 - linearity graph for Emtricitabine 
 
 
Figure No.8- linearity graph for Tenofovir Disoproxil 
Fumarate 
 
B. Accuracy 
The accuracy expresses the closeness of agreement between 
the true value which is accepted either as a conventional true 
value or an accepted reference value and the value found. 
Recovery study was performed by standard addition method 
by adding the known amount of Emtricitabine, Tenofovir , 
Disoproxil Fumarate (Reference standard) to the placebo at 
three different concentration levels i.e 50%, 100% and 150% 
of assay concentration and % recovery for all these drug 
were calculated.% Recoveries Emtricitabine, Tenofovir 
Disoproxil Fumarate were found in the range of 100.9-101.4 
%, and 100.0-100.99% respectively(RSD < 2) . 
 
 
Table No. 4 - Accuracy data of Emtricitabine 
Sr no 
Level of % 
Recovery 
Weight Taken 
(mg) 
Mg 
Recovered 
% recovery 
% mean 
recovery 
Emtricitabine 
50 100 101.74 101.8 
101.4 100 200 204.79 101.05 
150 300 300.07 100.9 
Tenofovir 
Disoproxil 
Fumarate 
50 150 151.18 101.7 
100.7 100 300 300.81 100.9 
150 450 450.54 100.1 
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C. Precision  
 Inter-day Precision 
The relative standard deviation for inter-day was found to be less than 2%. The %RSD of inter-day was 0.18% for Emtricitabine 
and 0.20 for Tenofovir Disoproxil Fumarate 
Table No. 5 – Inter-day Variability for Emtricitabine and Tenofovir Disoproxil Fumarate 
Emtricitabine Tenofovir Disoproxil Fumarate. 
Day 1 Area  Day 1 Area 
1416658 1296985 
1420559 1297677 
1422385 1298510 
Day 2 1419698 Day 2 1294590 
1418601 1295669 
1415587 1291530 
Mean  1418915 Mean 1295827 
% RSD  0.18% % RSD 0.20% 
 
Intraday Precision 
The relative standard deviation for intraday was found to be less than 2%. The %RSD of intraday was 0.26% for Emtricitabine 
and 0.42% for Tenofovir Disoproxil Fumarate. 
Table No. 6 – Intraday Variability for Emtricitabine and Tenofovir Disoproxil Fumarate 
Emtricitabine Tenofovir Disoproxil Fumarate. 
Morning Area  Morning Area 
141665 1296985 
1420559 1297677 
1422385 1298510 
Evening 1412145 Evening 1297137 
1415669 1308683 
1418339 1291939 
Mean  1417625.8 Mean 1298488.5 
% RSD  0.26% % RSD 0.42% 
 
D. Robustness 
Robustness is the measure of a method by deliberate changes in chromatographic condition such as change in PH, flow rate, 
wavelength. but result remain unaffected. 
Robustness was found to be satisfactory within the range. % RSD at different pH was found to be 0.268647394 for 
Emtricitabine and 0.282261806 for Tenofovir Disoproxil Fumarate. % RSD at different Wavelengths was found to be 
0.158228626 for Emtricitabine and 0.151856765 for Tenofovir Disoproxil Fumarate. 
a. At different pH 
 
Table No. 7: Robustness data of Emtricitabine & Tenofovir Disoproxil Fumarate at different Ph 
Drug Sample PH Area Mean SD % RSD 
 Emtricitabine Not adjust pH  878147       
 6.4 879413 877469 2357.298 0.268647394 
  7.0 874847       
Tenofovir Disoproxil Fumarate Not adjust pH 766242       
 6.4 763461 765807 2161.581 0.282261806 
 7.0 767718       
 
b. At Different Wavelengths 
Table No. 9 – Robustness data of Emtricitabine and Tenofovir Disoproxil Fumarate at different Wavelength 
Drug Sample Wavelength (nm) Area Mean SD % RSD 
  266 878147       
Emtricitabine 264 877838 878790.3333 1390.497872 0.158228626 
  268 880386       
  266 766242       
Tenofovir Disoproxil Fumarate 264 767597 767467 1165.450557 0.151856765 
  268 768562       
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E. Ruggedness – 
It is the degree of reproducibility of test results obtained by analysing the same sample under variety of normal test conditions 
such as different analysts, days, Sinstruments, reagents and column i.e. lack of influence of environmental variables on the 
method. 
Table No. 10 – Ruggedness data of Emtricitabine and Tenofovir Disoproxil Fumarate 
Concentration Of  
Emtricitabine (µg/ml) 
Area 
 Concentration Tenofovir Disoproxil 
Fumarate. (µg/ml) Area 
10 360371 15 285208 
20 881213 30 772702 
30 1423333 45 1308968 
40 1981950 60 1843778 
50 2565314 75 2379853 
 
F. Limit of Detection (LOD) and Limit of Quantitation (LOQ) 
Limit of Detection was found to be 0.182 µg/ml for Emtricitabine and 0.132 µg/ml for Tenofovir Disoproxil Fumarate. Limit of 
Quantitation was found to be 0.551 µg/ml for Emtricitabine and 0.401 µg/ml for Tenofovir Disoproxil Fumarate. Result are 
summarized in below table 
Table No. 11 – Limit of Detection (LOD) for Emtricitabine and Tenofovir Disoproxil Fumarate 
Sr. No  Name  Standard deviation  Slope LOD 
1 Emtricitab1ine 3038.45 55175 0.182 µg/ml\ 
2 Tenofovir Disoproxil Fumarate 2104.17 52523 0.132 µg/ml 
 
Table No. 12 – Limit of Quantitation (LOQ) for Emtricitabine and Tenofovir Disoproxil Fumarate 
Sr. No  Name  Standard deviation  Slope LOQ 
1 Emtricitabine 3038.45 55175 0.551 µg/ml 
2 Tenofovir Disoproxil Fumarate 2104.17 52523 0.401 µg/ml 
 
CONCLUSION  
The present study describes a simple and accurate RP HPLC-
method for the simultaneous determination of Emtricitabine 
& Tenofovir Disoproxil Fumarate in pharmaceutical dosage 
form. As per ICH guidelines all the outcomes of validations 
parameters are falling within the standard limits for 
individual parameters. No interference of the excipients was 
observed in formulation. It is concluded that this method 
exhibits high resolution with minimum tailing. 
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